• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090

Introduction to (S)-3-Aminoheptan-1-ol (CAS No. 1158985-17-1)

(S)-3-Aminoheptan-1-ol, with the chemical identifier CAS No. 1158985-17-1, is a significant compound in the field of pharmaceutical chemistry and biochemistry. This chiral amine derivative has garnered considerable attention due to its unique structural properties and potential applications in drug development and synthetic chemistry. The compound's stereochemistry, specifically its (S)-configuration, plays a crucial role in its biological activity and interactions with biological targets.

The molecular structure of (S)-3-Aminoheptan-1-ol consists of a seven-carbon chain terminated by an amine group at one end and a hydroxyl group at the other. This linear aliphatic amine is characterized by its high solubility in polar solvents, making it a versatile intermediate in organic synthesis. The (S)-configuration of the amine group contributes to its specific pharmacological profile, influencing its binding affinity and metabolic stability.

In recent years, there has been growing interest in the use of chiral amines like (S)-3-Aminoheptan-1-ol in the development of enantioselective drugs. Enantioselective drugs are designed to interact with only one enantiomer of a chiral molecule, often leading to improved efficacy and reduced side effects. The (S)-enantiomer of 3-aminoheptan-1-ol has shown promise in several preclinical studies, particularly in the context of central nervous system (CNS) disorders.

One of the most compelling applications of (S)-3-Aminoheptan-1-ol is its role as a building block in the synthesis of more complex pharmacophores. Researchers have leveraged its structural framework to develop novel compounds with potential therapeutic benefits. For instance, derivatives of this compound have been investigated for their potential as neuromodulators, targeting receptors involved in pain perception, mood regulation, and cognitive function.

The synthesis of (S)-3-Aminoheptan-1-ol typically involves chiral resolution or asymmetric synthesis methods to ensure high enantiomeric purity. Chiral resolution techniques such as diastereomeric salt formation followed by crystallization or chromatography are commonly employed. Asymmetric synthesis methods, including catalytic hydrogenation or enzymatic resolution, offer more efficient routes to produce enantiomerically pure compounds on an industrial scale.

Recent advancements in biocatalysis have also contributed to the production of high-purity (S)-3-Aminoheptan-1-ol. Enzymes such as lipases and esterases have been engineered to facilitate enantioselective transformations, providing sustainable and environmentally friendly alternatives to traditional synthetic methods. These biocatalytic approaches align with the growing emphasis on green chemistry principles in pharmaceutical manufacturing.

The pharmacological profile of (S)-3-Aminoheptan-1-ol has been extensively studied in various model systems. Preclinical data suggest that this compound exhibits moderate affinity for certain neurotransmitter receptors, including serotonin and dopamine receptors. These interactions have implications for potential applications in treating conditions such as depression, anxiety, and neurodegenerative diseases.

In addition to its neurological applications, research has explored the use of (S)-3-Aminoheptan-1-ol as a precursor for more complex bioactive molecules. Its structural motif is found in several natural products and drug candidates, highlighting its importance as a pharmacophoric scaffold. By modifying key functional groups or introducing additional substituents, researchers can tailor the properties of derived compounds to target specific biological pathways.

The safety profile of (S)-3-Aminoheptan-1-ol has also been evaluated through toxicological studies. Preliminary data indicate that the compound is well-tolerated at moderate doses, with minimal adverse effects observed in animal models. However, further studies are needed to fully assess its long-term safety and potential for off-target interactions.

The future prospects for (S)-3-Aminoheptan-1-ol are promising, with ongoing research focusing on optimizing synthetic routes and exploring new therapeutic applications. Collaborative efforts between academic institutions and pharmaceutical companies are likely to drive innovation in this area, leading to the development of novel drugs based on this versatile chiral amine.

In conclusion, (S)-3-Aminoheptan-1-ol (CAS No. 1158985-17-1) represents a valuable compound with significant potential in pharmaceutical research and development. Its unique stereochemistry and structural properties make it an attractive candidate for designing enantioselective drugs targeting various neurological and therapeutic indications. As research continues to uncover new applications for this compound, it is expected to play an increasingly important role in drug discovery and development efforts worldwide.

• 62870-50-2(1-Octanol, 7-amino-)
• 64197-80-4((S)-3-Aminohexan-1-ol)
• 104808-73-3(1-Hexanol, 3-amino-, hydrochloride)
• 82082-21-1(5-aminohexan-1-ol)
• 68889-62-3((S)-3-Aminohexan-1-ol hydrochloride)
• 927-55-9(4-Amino-1-pentanol)
• 27413-77-0(4-Amino-1,7-heptanediol)
• 1402805-31-5((3R)-3-Aminoheptan-1-ol;hydrochloride)
• 64197-81-5(1-Hexanol, 3-amino-, (3R)-)
• 68889-61-2(3-aminohexan-1-ol)